Novel immunotherapy combination produces durable response in frontline metastatic melanoma
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab is safe and produces a deep, durable response in previously untreated metastatic melanoma patients, according to findings published today in the Journal of Clinical Oncology, by researchers from Â鶹ӳ» MD Anderson Cancer Center.
Lead and corresponding...
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
Researchers from Â鶹ӳ» MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade...